PARP Traps Rescue the Pro-Inflammatory Response of Human Macrophages in the In Vitro Model of LPS-Induced Tolerance

Abstract

Secondary infections cause sepsis that lead to patient disability or death. Contact of macrophages with bacterial components (such as lipopolysaccharide—LPS) activates the intracellular signaling pathway downstream of Toll-like receptors (TLR), which initiate an immune proinflammatory response. However, the expression of nuclear factor-kappa B (NF-κB)-dependent proinflammatory cytokines significantly decreases after single high or multiple LPS stimulations. Knowing that poly(ADP-ribose) polymerase-1 (PARP1) serves as a cofactor of NF-κB, we aimed to verify a hypothesis of the possible contribution of PARP1 to the development of LPS-induced tolerance in human macrophages. Using TNF-α mRNA expression as a readout, we demonstrate that PARP1 interaction with the TNF-α promoter, controls macrophage immunoparalysis. We confirm that PARP1 is extruded from the gene promoter, whereas cell pretreatment with Olaparib maintains macrophage responsiveness to another LPS treatment. Furthermore, cell pretreatment with proteasome inhibitor MG132 completely abrogates the effect of Olaparib, suggesting that PARP1 acts with NF-κB in the same regulatory pathway, which controls pro-inflammatory cytokine transcription. Mechanistically, PARP1 trapping allows for the re-rebinding of p65 to the TNF-α promoter in LPS-stimulated cells. In conclusion, PARP traps prevent PARP1 extrusion from the TNF-α promoter upon macrophage stimulation, thereby maintaining chromatin responsiveness of TLR activation, allowing for the re-binding of p65 and TNF-α transcription.

Inhibition of the TLR/NF-κB Signaling Pathway and Improvement of Autophagy Mediates Neuroprotective Effects of Plumbagin in Parkinson’s Disease

“…During quiescence, NF-κB heterodimers (p50 and p65) are inactive in the cytoplasm, coupled to protein κB inhibitors (IκB). In contrast, NF-κB is activated and initiates transcription of downstream target genes such as TNF-α, IL-1β, and IL-6 [42][43][44] when IκBα is phosphorylated and degraded, allowing the NF-κB dimer p50 and p65 to enter the nucleus. Therefore, indicators of NF-κB activation include nuclear p65 expression and the generation of inflammatory cytokines.…”

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy

“…The role of PARPis is essentially to shift this sort of chronic inflammation to a more immune-responsive TME through widespread effects on cells involved in innate and adaptive immune response and soluble factors [ 48 ]. PARPis block the transcription of lipopolysaccharide-induced macrophage cytokines and other pro-inflammatory cytokines promoting TAMs differentiation towards the M2 subtype, associated with tumor invasion and spread [ 78 , 79 ]. PARPis enhance APCs by upregulating MHC after activating ATM/ATR kinases, leading to CD8 + and CD4 + T-cells activation [ 51 , 74 , 80 ].…”

Telomere attrition and inflammation: the chicken and the egg story

“…This makes it impossible to lengthen the telomere again [54]. PARP-1 also acts as a transcriptional coactivator for NF-κB promoting cytokines and adhesion molecules expression for facilitating immune cell interaction and portrays a vicious cycle model [55] Another research study has revealed that yes-associated protein 1 (YAP1) transcription coactivator is upregulated via ataxia-telangiectasia mutated (ATM)/c-ABL pathway in DNA damage signaling through telomere dysfunction in inflammatory bowel diseases. Activated YAP1 elevates several inflammatory bowel disease (IBD) pertinent genes like the pro-inflammatory cytokines including premature interleukin-18 (IL-18).…”